ARID1A and neoplasm: Mutational inactivation of ARID1A leads to dysregulation in the PI3K/AKT pathway, WNT pathway, DNA damage response, and tumor immune microenvironment [5–7], suggesting ARID1A is a potential therapeutic target in CRC.